3,5-di-tert-butyl-2-(2,2-difluoroethoxy)iodobenzene | 460048-41-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,5-di-tert-butyl-2-(2,2-difluoroethoxy)iodobenzene
• 英文别名: 1,5-Di-tert-butyl-2-(2,2-difluoro-ethoxy)-3-iodo-benzene；1,5-Di-tert-butyl-2-(2,2-difluoroethoxy)-3-iodo-benzene；1,5-ditert-butyl-2-(2,2-difluoroethoxy)-3-iodobenzene
• CAS: 460048-41-3
• 化学式: C₁₆H₂₃F₂IO
• 分子量: 396.259
• InChiKey: VVTGWKTXRIRQTE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3,5-di-tert-butyl-2-(2,2-difluoroethoxy)iodobenzene 在 bis(acetylacetonate)nickel(II) 、 copper(l) iodide 、 四(三苯基膦)钯 、 TEA 、 一氯化碘 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 N-甲基吡咯烷酮 、 四氯化碳 为溶剂， 生成 1,5-ditert-butyl-2-(2,2-difluoroethoxy)-3-[(Z)-1-iodoprop-1-en-2-yl]benzene
  参考文献：
  名称：

  Design and synthesis of fluorinated RXR modulators

  摘要：

  Fluorinated trienoic acid analogues of the RXR selective modulator 1 (LG101506) were synthesized, and tested for their ability to bind RXRalpha and activate RXR homo and heterodimers. Potency and efficacy were observed to be dependent upon the position of fluorination, and improvement in pharmacological profile was demonstrated in some cases. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00703-0
• 作为产物：
  描述：

  2,4-二叔丁基苯酚 在 N-碘代丁二酰亚胺 、 caesium carbonate 、 对甲苯磺酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 3,5-di-tert-butyl-2-(2,2-difluoroethoxy)iodobenzene
  参考文献：
  名称：

  Design, Synthesis, and Structure−Activity Relationship Studies of Novel 6,7-Locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic Acids

  摘要：

  Retinoid X receptor:peroxisome proliferative-activated receptor (RXR:PPAR) heterodimers play a critical role in the regulation of glucose (RXR/PPARy) and lipid metabolism (RXR/PPARalpha). Previously, we described a concise structure-activity relationship study of selective RXR modulators possessing a (2E,4E,6Z)-3-methyl-7-(3,5-dialkyl-6-Eilkoxyphenyl)-octa-2,4,6-trienoic acid scaffold. These studies were focused on the 2-position alkoxy side chain. We describe here the design and synthesis of a novel series of RXR selective modulators possessing the same aromatic core structure with the addition of a ring locked 6--7-Z-olefin on the trienoic acid moiety. The synthesis and structure- activity relationship studies of these 6,7-locked cyclopentenyl, phenyl, thienyl, furan, and pyridine-trienoic acid derivatives is presented herein.

  DOI：

  10.1021/jm020401k

文献信息

• Retinoid x receptor modulators
  申请人：——

  公开号：US20040167160A1

  公开（公告）日：2004-08-26

  The present invention is directed to compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof: (I). The invention is also directed to pharmaceutical compositions, methods of use and methods of making compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof.

  本发明涉及由结构式（I）表示的化合物及其药用可接受的盐、溶剂合物和水合物：（I）。该发明还涉及由结构式（I）表示的化合物及其药用可接受的盐、溶剂合物和水合物的药物组合物、使用方法和制备方法。
• Fluorinated trienes and their use as rxr modulators
  申请人：——

  公开号：US20040248919A1

  公开（公告）日：2004-12-09

  The present invention relates to a method of modulating retinoid X receptor activity in a mammal, novel compounds and pharmaceutical compositions for modulating retinoid X receptor activity in a mammal, and methods of making compounds that modulate retinoid X receptor activity in a mammal. The compounds are represented by Structural Formula 1: The compounds of Structural Formual 1 are efficacious insulin sensitizers and do not have the undesirable side effects of increasing triglycerides or suppressing the thyroid hormone axis. 1

  本发明涉及一种调节哺乳动物中视黄醇X受体活性的方法，用于调节哺乳动物中视黄醇X受体活性的新型化合物和制备调节哺乳动物中视黄醇X受体活性的化合物的方法。这些化合物由结构式1表示：结构式1的化合物是有效的胰岛素敏化剂，并且不具有增加三酰甘油或抑制甲状腺激素轴的不良副作用。
• Retinoid X receptor modulators
  申请人：Eli Lilly and Company

  公开号：US07348359B2

  公开（公告）日：2008-03-25

  The present invention is directed to compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof: (I). The invention is also directed to pharmaceutical compositions, methods of use and methods of making compounds represented by Structural Formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof.

  本发明涉及由结构式（I）表示的化合物及其药学上可接受的盐、溶剂和水合物：（I）。本发明还涉及由结构式（I）表示的化合物及其药学上可接受的盐、溶剂和水合物的制备方法、药物组合物和使用方法。
• Design, synthesis and structure–activity relationship of novel RXR-selective modulators
  作者：Pierre-Yves Michellys、Jennifer D'Arrigo、Timothy A. Grese、Donald S. Karanewsky、Mark D. Leibowitz、Dale A. Mais、Christopher M. Mapes、Anne Reifel-Miller、Deepa Rungta、Marcus F. Boehm

  DOI：10.1016/j.bmcl.2003.12.089

  日期：2004.3

  The synthesis and in vitro characterization of novel RXR-selective ligands possessing various substituted 1-benzofuran or 1-benzothiophene moieties are described. (C) 2004 Elsevier Ltd. All rights reserved.
• FLUORINATED TRIENES AND THEIR USE AS RXR MODULATORS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1368296A1

  公开（公告）日：2003-12-10